The provision of any new prevention product in clinical trial settings is often vastly different from implementation in “real life” public sector settings. In addition, use of antiretrovirals (ARV), such as tenofovir gel, for pre-exposure prophylaxis requires regular HIV testing to ensure users are uninfected before initiating and continuing product use. Therefore, before any ARV-based prevention product can be introduced to women, information is needed on HIV testing practices, how best to integrate products into existing primary health care systems, and women’s risk perception and health-seeking behaviors. The Population Council, in partnership with Solutions IPPT, conducted a study to learn more about women’s experiences in routine primary health care centers in Mpumalanga, South Africa to inform microbicides introduction. This report discusses the issues explored in the study: service seeking, constellation of services, HIV testing behavior, self-assessment of risk, and interest in tenofovir gel.
Brady, Martha, Saiqa Mullick, Barbara Friedland, Marlena Gehret Plagianos, Linda Du Plessis, and Thabiso Mango. 2015. "Learning from women about HIV risk, HIV testing behaviors, and prevention practices in Mpumalanga, South Africa: A descriptive study to inform microbicides introduction." New York: Population Council.